# Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts

> **NCT01701674** · NA · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 13 (actual)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **DRUG:** Ipilimumab
- **PROCEDURE:** Tumor Infiltrating Lymphocytes (TIL)
- **DRUG:** Administration of Lymphodepletion
- **DRUG:** Cyclophosphamide as Part of Lymphodepletion
- **DRUG:** Fludarabine as Part of Lymphodepletion
- **DRUG:** High Dose IL-2
- **BIOLOGICAL:** Adoptive Cell Therapy with TIL

## Key facts

- **NCT ID:** NCT01701674
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10-09
- **Primary completion:** 2016-04-21
- **Final completion:** 2025-08-21
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2025-12-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01701674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01701674, "Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01701674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*